{"title":"Oral Sprays","description":"\u003cp\u003eOral Sprays research catalog from US Peptide Labs.\u003c\/p\u003e","products":[{"product_id":"glp-3rt-oral","title":"GLP-3RT Oral Spray","description":"\u003ch3\u003eGLP-3RT — oral format\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003e15mL Oral Spray\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThis listing supplies the compound in an orally administered format rather than a lyophilized vial requiring reconstitution. Oral and sublingual routes are studied for peptides because they remove injection handling from the workflow, while raising well-documented questions about gastrointestinal stability and absorption that vary by compound and formulation. The research summarised below was generated across multiple routes; the reported-amounts table records the route for each figure. Nothing here claims equivalence between routes.\u003c\/p\u003e\u003cp\u003eBecause this oral format is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized GLP-3RT vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eIncretin-pathway triple agonist (GIP \/ GLP-1 \/ glucagon receptor)\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eGLP-3RT (LY3437943) is an investigational peptide agonist engineered to activate three receptors in the incretin\/glucagon family: GIP, GLP-1, and glucagon receptors. It has been evaluated in company-sponsored clinical trials, including a prominent phase 2 obesity study published in the New England Journal of Medicine and earlier multiple-ascending-dose work in type 2 diabetes.\u003c\/p\u003e\u003cp\u003eResearchers focus on GLP-3RT because dual and triple agonists extend the pharmacology already established for GLP-1 receptor agonists. In the phase 2 obesity trial, once-weekly subcutaneous escalation regimens produced substantial, dose-dependent mean body-weight reductions over 48 weeks compared with placebo, alongside metabolic marker changes typical of this class. Gastrointestinal adverse events were the most frequently discussed tolerability theme, consistent with incretin mimetics.\u003c\/p\u003e\u003cp\u003eEducational dosage content should cite trial arms and titration schedules as documented research protocols. GLP-3RT remains investigational for the indications studied in those papers and is not framed here as consumer guidance. Research-use discussions of vial sizes outside formal trials must stay clearly separated from labeled clinical development doses.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eGLP-3RT simultaneously engages GIP receptor, GLP-1 receptor, and glucagon receptor pathways. GLP-1 receptor activation is associated with enhanced glucose-dependent insulin secretion, slowed gastric emptying, and central appetite signaling. GIP receptor activity adds another incretin axis that may support insulinotropic and adipose-tissue effects in combination regimens. Glucagon receptor engagement is explored for energy-expenditure and hepatic lipid-metabolism contributions. The triple design aims to combine reduced energy intake with metabolic effects not fully captured by GLP-1 agonism alone.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eobesity clinical research\u003c\/li\u003e\n\u003cli\u003etype 2 diabetes\u003c\/li\u003e\n\u003cli\u003eincretin pharmacology\u003c\/li\u003e\n\u003cli\u003ebody-weight regulation\u003c\/li\u003e\n\u003cli\u003ecardiometabolic markers\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eEndocrinology and obesity-medicine trialists, metabolic pharmacologists, and translational teams comparing multi-receptor agonists with GLP-1 S- or GLP-2T-class agents. Academic groups analyze body-composition and liver-fat secondary endpoints. This audience is clinical-research oriented rather than cosmetic or injury-repair focused.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e1 mg – 12 mg\u003c\/td\u003e\n\u003ctd\u003eonce weekly\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003ePhase 2 obesity trial maintenance dose arms (Jastreboff et al., NEJM 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e500 mcg – 12 mg\u003c\/td\u003e\n\u003ctd\u003eonce weekly (study-defined)\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003ePhase 1b multiple-ascending-dose work in type 2 diabetes (LY3437943)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eFollow manufacturer or trial pharmacy instructions for investigational product. Research lyophilizates are typically kept refrigerated, protected from light; reconstituted multi-dose research vials are refrigerated and timed to supplier stability limits. Do not freeze reconstituted solutions unless a COA explicitly allows it.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eFormal trials study GLP-3RT as monotherapy against placebo or active comparators, not as part of informal peptide stacks. Combining with other incretin agents would duplicate pathway stimulation and is outside evidence-based research design. Lifestyle and background diabetes medications in trials are protocol-defined, not ad-hoc stacks.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e15mL Oral Spray\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eLY3437943, triple agonist, GGG tri-agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eEngineered for once-weekly administration in clinical development (long-acting incretin-class peptide kinetics)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWhat is the dosage for GLP-3RT?\u003c\/strong\u003e\u003cbr\u003eIn the landmark phase 2 obesity trial, participants received once-weekly subcutaneous GLP-3RT with maintenance doses of 1 mg, 4 mg, 8 mg, or 12 mg after escalation at higher strengths. Those figures are documented clinical-research arms, not a consumer recommendation. Always cite the primary NEJM protocol when discussing dose.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow much bac water for GLP-3RT?\u003c\/strong\u003e\u003cbr\u003eTrial product is pharmacy-prepared; research vials sold as lyophilized powder require label-specific diluent volumes. Choose a diluent volume that makes weekly mg doses easy to measure on an insulin syringe (for example, concentrating so that 0.1-0.5 mL matches the intended mg). Calculate from vial_mg \/ mL.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eGLP-3RT dosage per day\u003c\/strong\u003e\u003cbr\u003eClinical development uses weekly—not daily—dosing. Dividing a weekly mg amount into daily micro-doses is not how the phase 2 obesity protocol was written. Educational charts should show mg per week and titration steps.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eGLP-3RT dosage chart\u003c\/strong\u003e\u003cbr\u003eA literature-faithful chart lists escalation steps toward 4, 8, or 12 mg weekly maintenance, including the lower 1 mg arm. Higher-dose groups in phase 2 used gradual increases every four weeks to improve gastrointestinal tolerability. Reproduce numbers from the peer-reviewed methods section.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow long does GLP-3RT take?\u003c\/strong\u003e\u003cbr\u003eIn the 48-week phase 2 obesity study, mean weight-change curves separated over months, with large effects reported by week 48 at higher doses. Early gastrointestinal symptoms, when they occur in incretin trials, often appear during escalation. Timelines are trial endpoints, not guarantees for any individual.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhat is the half life of GLP-3RT?\u003c\/strong\u003e\u003cbr\u003eGLP-3RT was designed as a long-acting molecule compatible with once-weekly subcutaneous dosing. Exact terminal half-life values should be taken from clinical pharmacology sections of sponsor publications rather than informal blogs.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCan GLP-3RT be stacked with other peptides?\u003c\/strong\u003e\u003cbr\u003ePivotal studies evaluate it alone within controlled backgrounds. Stacking with other GLP-1 or GIP agents is not an evidence-based research protocol and may compound mechanism-overlapping effects. Educational sites should discourage casual polypharmacy framing.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow is GLP-3RT dosage calculated from a research vial?\u003c\/strong\u003e\u003cbr\u003emg_dose = concentration_mg_per_mL x mL_drawn. If a 20 mg vial is reconstituted with 2 mL, concentration is 10 mg\/mL, so 0.4 mL provides 4 mg. Use a calculator and dual-check units before any research preparation.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eTriple-Hormone-Receptor Agonist GLP-3RT for Obesity - A Phase 2 Trial.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36354040\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eLY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37385280\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eGLP-3RT, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","brand":"US Peptide Labs","offers":[{"title":"20mg","offer_id":44076219662423,"sku":"CW\/P-RET20O","price":220.0,"currency_code":"USD","in_stock":true},{"title":"40mg","offer_id":44076811878487,"sku":"CW\/P-RET40O","price":350.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/glp-3rt-oral-20mg.png?v=1790198576"},{"product_id":"nad-oral","title":"NAD+ Oral Spray","description":"\u003ch3\u003eNAD+ — oral format\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003e15mL Oral Spray\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThis listing supplies the compound in an orally administered format rather than a lyophilized vial requiring reconstitution. Oral and sublingual routes are studied for peptides because they remove injection handling from the workflow, while raising well-documented questions about gastrointestinal stability and absorption that vary by compound and formulation. The research summarised below was generated across multiple routes; the reported-amounts table records the route for each figure. Nothing here claims equivalence between routes.\u003c\/p\u003e\u003cp\u003eBecause this oral format is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized NAD+ vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eredox coenzyme and NAD biology research compound\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eNAD+ is not a peptide; it is a nucleotide-derived coenzyme used in virtually every cell. Research interest centers on its role in redox reactions, mitochondrial metabolism, sirtuin signaling, PARP activity, and age-associated changes in cellular energy handling. Education pages often group NAD+ with peptide protocols because it is sold in similar lyophilized formats, but mechanistically it belongs to metabolism and coenzyme biology.\u003c\/p\u003e\u003cp\u003ePublished human work most often studies NAD+ precursors such as nicotinamide riboside or nicotinamide mononucleotide, while direct NAD+ material appears in more limited pharmacokinetic and infusion-oriented discussions. Any research-grade NAD+ powder is Research Use Only and is not the same thing as a regulated drug product. Reported ranges below are reference points from published precursor or NAD-related literature, not instructions for use.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eNAD+ cycles between oxidized and reduced forms to shuttle electrons through glycolysis, the TCA cycle, and oxidative phosphorylation. It also serves as a substrate for enzymes including sirtuins, PARPs, CD38, and other NAD-consuming systems. When NAD+ availability changes, downstream effects can include altered mitochondrial respiration, DNA damage signaling, inflammatory tone, and cellular stress responses. Researchers study both direct NAD+ and precursor strategies because cells tightly regulate NAD synthesis, salvage, and consumption.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003emitochondrial function\u003c\/li\u003e\n\u003cli\u003eaging biology\u003c\/li\u003e\n\u003cli\u003eredox metabolism\u003c\/li\u003e\n\u003cli\u003ecellular stress response\u003c\/li\u003e\n\u003cli\u003eNAD precursor pharmacology\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eNAD+ is studied by mitochondrial biologists, aging researchers, nutrition scientists, and pharmacologists. Clinical investigators more commonly study oral NAD+ precursors, while analytical labs examine NAD+ handling, stability, and compartment-specific measurement.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e300 mg – 1000 mg\u003c\/td\u003e\n\u003ctd\u003edaily in study protocols\u003c\/td\u003e\n\u003ctd\u003eoral\u003c\/td\u003e\n\u003ctd\u003eHuman oral nicotinamide riboside studies commonly cited in NAD+ precursor literature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e900 mg\u003c\/td\u003e\n\u003ctd\u003esingle study dose\u003c\/td\u003e\n\u003ctd\u003eoral\u003c\/td\u003e\n\u003ctd\u003eAcute human cerebral NAD+ measurement study using nicotinamide riboside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eResearch-grade lyophilized NAD+ is commonly stored frozen and protected from moisture and light; reconstituted material is typically kept refrigerated and used promptly in laboratory settings.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eNAD+ is often discussed beside mitochondrial and recovery-focused compounds, but the strongest literature is on NAD metabolism rather than peptide stacking. Researchers usually separate NAD+ or precursor variables from other interventions so changes in redox markers, methylation demand, and mitochondrial readouts can be interpreted cleanly.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e15mL Oral Spray\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003enicotinamide adenine dinucleotide, oxidized NAD, NAD plus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eContext-dependent; circulating NAD+ and precursors are rapidly metabolized, while downstream NAD pool changes may last longer than plasma exposure.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003ewhat is the dosage for NAD+\u003c\/strong\u003e\u003cbr\u003eFor education only: published human studies most often report oral NAD+ precursor amounts, commonly in the hundreds of milligrams to 1 gram daily. That is not a recommendation and is not the same as dosing research-grade NAD+.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow much bacteriostatic water for NAD+\u003c\/strong\u003e\u003cbr\u003eResearch suppliers commonly discuss 5-20 mL reconstitution volumes for larger NAD+ vials, depending on target concentration. Reconstitution math is a lab calculation, not a human-use instruction.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eNAD+ dosage per day\u003c\/strong\u003e\u003cbr\u003eDaily values in the literature usually refer to oral precursors such as nicotinamide riboside. Direct NAD+ protocols vary by research model and should be read from the original paper.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eNAD+ dosage chart\u003c\/strong\u003e\u003cbr\u003eA useful chart should separate precursor studies, direct NAD+ analytical work, route, concentration, and species. Combining them into one dosing chart can be misleading.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow long does NAD+ take\u003c\/strong\u003e\u003cbr\u003eSome precursor studies measure NAD-related metabolites within hours, while tissue or functional endpoints are usually assessed over weeks. Timing depends on the assay and model.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eNAD+ half life\u003c\/strong\u003e\u003cbr\u003eThere is no single practical half-life for all NAD+ research because NAD+ is rapidly turned over and compartmentalized. Researchers often track metabolite pools rather than plasma half-life alone.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ecan NAD+ be stacked\u003c\/strong\u003e\u003cbr\u003eIt can be studied alongside other compounds, but clean protocols isolate variables. Research-use-only material should not be treated as a wellness stack or drug substitute.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37068054\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eDietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29599478\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eChronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39044608\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eAcute nicotinamide riboside supplementation increases human cerebral NAD(+) levels in vivo.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","brand":"US Peptide Labs","offers":[{"title":"500mg","offer_id":44076219891799,"sku":"CW\/P-NAD500O","price":125.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/oral-nadplus-500mg.png?v=1785621411"},{"product_id":"tesamorelin-oral","title":"Tesamorelin Oral Spray","description":"\u003ch3\u003eTesamorelin — oral format\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003e15mL Oral Spray\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThis listing supplies the compound in an orally administered format rather than a lyophilized vial requiring reconstitution. Oral and sublingual routes are studied for peptides because they remove injection handling from the workflow, while raising well-documented questions about gastrointestinal stability and absorption that vary by compound and formulation. The research summarised below was generated across multiple routes; the reported-amounts table records the route for each figure. Nothing here claims equivalence between routes.\u003c\/p\u003e\u003cp\u003eBecause this oral format is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized Tesamorelin vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eGrowth hormone-releasing hormone (GHRH) analog\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eTesamorelin is a stabilized analog of growth hormone-releasing hormone that stimulates pituitary GH secretion, raising IGF-1 and influencing body composition. It is distinctive among research-discussed peptides because a specific formulation received FDA approval to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.\u003c\/p\u003e\u003cp\u003ePhase 3 programs led by Falutz and colleagues demonstrated meaningful reductions in visceral adipose tissue over 26 weeks with daily subcutaneous administration, with extension data informing durability and metabolic secondary endpoints. Separate work evaluated liver fat and other cardiometabolic markers in HIV populations with central fat accumulation. These papers are the correct primary anchors for dosage education.\u003c\/p\u003e\u003cp\u003eOutside labeled use, tesamorelin appears in broader body-composition research conversations. Educational content should keep approved indication, trial doses, and off-label speculation clearly separated, and should use research-use-only language for non-labeled contexts. This page summarizes documented ranges for reference by research professionals.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eTesamorelin binds pituitary GHRH receptors, amplifying physiologic GH pulsatility rather than supplying exogenous growth hormone directly. Increased GH acts on hepatic and peripheral tissues to raise IGF-1, promote lipolysis in visceral fat depots, and support lean-mass signals. Preferential VAT reduction with relative subcutaneous fat sparing was a recurring theme in HIV lipodystrophy trials. Downstream metabolic effects on triglycerides and hepatic fat have been examined as secondary physiology.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eHIV-associated lipodystrophy\u003c\/li\u003e\n\u003cli\u003evisceral adiposity\u003c\/li\u003e\n\u003cli\u003eGH\/IGF-1 axis\u003c\/li\u003e\n\u003cli\u003ehepatic fat in endocrine research\u003c\/li\u003e\n\u003cli\u003ebody composition\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eInfectious-disease and endocrinology investigators working on HIV metabolic complications are the core clinical-research audience. Body-composition and NAFLD-oriented teams analyze VAT and liver-fat imaging endpoints. Peptide educators reference tesamorelin as a fully specified GHRH-analog case study with published phase 3 dose regimens.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2 mg\u003c\/td\u003e\n\u003ctd\u003eonce daily\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003ePivotal HIV lipodystrophy clinical trials (original 2 mg daily subcutaneous regimen)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1 mg – 2 mg\u003c\/td\u003e\n\u003ctd\u003edaily\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eResearch discussions of GH-axis body-composition protocols referencing the clinical dose anchor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eApproved product labeling specifies controlled storage and reconstitution steps; research lyophilizates should remain refrigerated per COA. Use diluent only as directed, refrigerate reconstituted solution, and discard after the labeled period.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eClinical trials evaluate tesamorelin on optimized antiretroviral and lifestyle backgrounds, not stacked with other GH secretagogues. Combining GHRH analogs with GHRPs\/ghrelin mimetics is sometimes hypothesized to amplify GH release but introduces confounding and safety-monitoring complexity. Research designs usually isolate the GHRH analog.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e15mL Oral Spray\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eTH9507, Egrifta, GHRH(1-44) analog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eShort plasma half-life consistent with a GHRH-analog peptide; clinical effect is mediated via stimulated GH\/IGF-1 axis rather than continuous plasma presence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWhat is the dosage for tesamorelin?\u003c\/strong\u003e\u003cbr\u003ePivotal HIV-associated lipodystrophy trials used 2 mg subcutaneously once daily for the original formulation. That is the best-documented human dose anchor in the peer-reviewed literature. Newer branded presentations may list different nominal milligram strengths that are designed to be exposure-matched—always read the specific label or trial protocol.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow much bac water for tesamorelin?\u003c\/strong\u003e\u003cbr\u003eFollow the product's reconstitution instructions when using approved kits. For research lyophilized vials, choose a diluent volume that delivers 2 mg in a convenient syringe volume (for example, 2 mg in 1 mL yields 2 mg\/mL). Do not assume multi-peptide blend volumes apply.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eTesamorelin dosage per day\u003c\/strong\u003e\u003cbr\u003eDaily dosing—not weekly—is the regimen used in the major VAT-reduction trials. Educational charts should show mcg or mg per day and note morning abdominal subcutaneous administration patterns described in clinical materials.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eTesamorelin dosage chart\u003c\/strong\u003e\u003cbr\u003eA simple chart maps 2 mg daily to syringe units at your concentration. If reconstituted to 2 mg\/mL, 1.0 mL = 2 mg. IGF-1 monitoring schedules from clinical practice are separate from the injection-volume chart and belong in protocol documents.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow long does tesamorelin take?\u003c\/strong\u003e\u003cbr\u003ePrimary VAT imaging endpoints in phase 3 work were assessed at 26 weeks, with extension observations to 52 weeks in some analyses. Benefits on visceral fat were treatment-dependent in follow-up discussions. Timelines refer to trial populations with HIV-associated central fat accumulation.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhat is the half life of tesamorelin?\u003c\/strong\u003e\u003cbr\u003eAs a peptide GHRH analog, plasma persistence is short; pharmacodynamic effects run through GH secretion and IGF-1 elevation lasting longer than the parent peptide's plasma spike. Cite clinical pharmacology references for numeric half-life values.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCan tesamorelin be stacked with other peptides?\u003c\/strong\u003e\u003cbr\u003eEvidence-based protocols study it as a single GH-axis agent. Stacking with CJC-1295, ipamorelin, or exogenous GH overlaps pathways and is not how pivotal trials were run. Research clarity favors monotherapy plus defined background care.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20101189\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eEffects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20554713\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eEffects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25038357\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eEffect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/22298602\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eTesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","brand":"US Peptide Labs","offers":[{"title":"10mg","offer_id":44076219924567,"sku":"CW\/P-TES10O","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/oral-tesamorelin-10mg.png?v=1785621414"},{"product_id":"oxytocin-oral-spray","title":"Oxytocin Oral Spray","description":"\u003ch3\u003eOxytocin — oral format\u003c\/h3\u003e\u003cp\u003eThis listing supplies the compound in an orally administered format rather than a lyophilized vial requiring reconstitution. Oral and sublingual routes are studied for peptides because they remove injection handling from the workflow, while raising well-documented questions about gastrointestinal stability and absorption that vary by compound and formulation. The research summarised below was generated across multiple routes; the reported-amounts table records the route for each figure. Nothing here claims equivalence between routes.\u003c\/p\u003e\u003cp\u003eBecause this oral format is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized Oxytocin vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eEndogenous nonapeptide hormone\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eOxytocin is an endogenous nonapeptide synthesized in the hypothalamus and released by the posterior pituitary. It is among the most thoroughly characterized peptides in human medicine because of long-standing obstetric uses, while a parallel research literature explores social cognition, stress responsivity, metabolic signals, and pain processing.\u003c\/p\u003e\u003cp\u003ePharmacologically, oxytocin is notable for a very short plasma half-life after intravenous dosing, which is why obstetric protocols often rely on controlled infusions. Research outside obstetrics frequently uses intranasal delivery when central nervous system questions are in view; subcutaneous routes appear in selected experimental pain and animal studies. A 2024 randomized trial reported that a low microgram-range subcutaneous dose modulated heat-pain ratings in healthy adults, adding a peer-reviewed SC data point.\u003c\/p\u003e\u003cp\u003eEducational dosage content must separate approved obstetric regimens, intranasal social-neuroscience doses (often 24 IU in experimental paradigms), and research-peptide vial math. This page is research-and-education oriented with research-use-only framing for non-labeled contexts—not a guide for unsupervised hormone use.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eOxytocin binds the G protein-coupled oxytocin receptor (OXTR), expressed in uterus, mammary tissue, brain circuits, and peripheral sites. Receptor activation engages phospholipase C and calcium-dependent pathways that drive uterine smooth-muscle contraction and milk ejection in physiologic contexts. Centrally, OXTR signaling modulates social salience, anxiety-related circuits, and autonomic tone in experimental paradigms. Peripheral analgesic effects discussed in recent SC research may involve local receptor mechanisms in addition to any central actions.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eobstetric pharmacology\u003c\/li\u003e\n\u003cli\u003esocial neuroscience\u003c\/li\u003e\n\u003cli\u003estress and affiliation biology\u003c\/li\u003e\n\u003cli\u003eexperimental pain modulation\u003c\/li\u003e\n\u003cli\u003emetabolic and autonomic research\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eObstetric clinical pharmacologists, affective and social neuroscientists, pain researchers, and endocrinology labs mapping OXTR distribution all work with oxytocin. Behavioral science groups dominate the intranasal literature. Peptide-education audiences often arrive via research-vial contexts and need help distinguishing IU obstetric dosing from mcg research vials.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e4 mcg\u003c\/td\u003e\n\u003ctd\u003esingle-dose experimental\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eExperimental subcutaneous research (example peer-reviewed human SC study)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eno single figure reported\u003c\/td\u003e\n\u003ctd\u003estudy-defined (often single or limited repeated sessions)\u003c\/td\u003e\n\u003ctd\u003eintranasal\u003c\/td\u003e\n\u003ctd\u003eCommon intranasal experimental neuroscience paradigms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10 mcg – 100 mcg\u003c\/td\u003e\n\u003ctd\u003evaries widely in informal sources\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eSecondary research-peptide discussions of SC ranges (less standardized than obstetric IV\/IM labeling)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eProtect from heat and light; refrigerated storage is standard for oxytocin preparations. Reconstituted research solutions should be kept cold, tightly capped, and discarded per stability guidance. Oxytocin is oxidation- and temperature-sensitive relative to hardier lyophilized research peptides.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eNeuroscience studies typically administer oxytocin alone when measuring social or stress endpoints. Combining with other neuropeptides confounds interpretation of OXTR-specific effects. Obstetric clinical protocols likewise do not stack research peptides; they follow labeled labor or postpartum pathways under medical supervision.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eOXT, OT, alpha-hypophamine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eAbout 1-6 minutes plasma half-life after IV administration commonly cited; effective central effects after intranasal dosing are discussed on longer behavioral timescales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWhat is the dosage for oxytocin peptide?\u003c\/strong\u003e\u003cbr\u003eIt depends entirely on context. Obstetric labeling uses IU for IV infusion or IM injection under clinical care. Social neuroscience often studies about 24 IU intranasally. A 2024 pain trial used 4 mcg subcutaneously as a single experimental dose. Research-vial mcg charts are not interchangeable with labor-and-delivery orders.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow much bac water for oxytocin?\u003c\/strong\u003e\u003cbr\u003eFor a 10 mg research vial, even 2-3 mL produces a very concentrated solution relative to low-mcg experimental targets, so serial dilution may be required for accurate microgram dosing. Document every dilution step. Clinical products arrive with their own diluents and concentrations.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eOxytocin dosage per day\u003c\/strong\u003e\u003cbr\u003eThere is no general per-day research standard analogous to once-weekly incretins. Obstetric use is continuous or event-driven. Behavioral studies are usually session-based. Chronic daily SC schedules online should be treated skeptically without primary support.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eOxytocin dosage chart\u003c\/strong\u003e\u003cbr\u003eSeparate charts by route: IU for labeled obstetric products, IU for intranasal experimental sprays, and mcg for reconstituted research vials. Include the conversion note that product-specific IU-mcg relationships must be confirmed on the label.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow long does oxytocin take?\u003c\/strong\u003e\u003cbr\u003eIV obstetric effects on uterine tone can appear within minutes. Intranasal behavioral tasks are often timed 30-45 minutes after dosing in experimental protocols. SC analgesic endpoints in the 2024 trial were assessed in the post-injection experimental window defined by that study.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhat is the half life of oxytocin?\u003c\/strong\u003e\u003cbr\u003ePlasma half-life after IV dosing is commonly summarized around 1-6 minutes (sometimes cited near 3-5 minutes), which is why infusions are used clinically. Intranasal and SC kinetics differ; central behavioral effects are not identical to plasma half-life.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCan oxytocin be stacked with other peptides?\u003c\/strong\u003e\u003cbr\u003eControlled research almost always isolates oxytocin when OXTR questions matter. Stacking with other neuroendocrine peptides muddies receptor-level inference. Clinical obstetric care follows dedicated protocols, not peptide stacks.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow is oxytocin dosage calculated from a research vial?\u003c\/strong\u003e\u003cbr\u003eConvert vial mg to mcg (1 mg = 1,000 mcg), divide by diluent mL to get mcg\/mL, then multiply by mL drawn. Because target experimental mcg amounts can be tiny, use adequate dilution and a precision syringe. Cross-check with a dosage calculator and a second person when preparing research aliquots.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38642595\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eSubcutaneous Oxytocin Injection Reduces Heat Pain: A Randomized-Controlled Trial.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/8568623\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eBioavailability and pharmacokinetics of sublingual oxytocin in male volunteers.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31286109\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eLong-Acting and Selective Oxytocin Peptide Analogs Show Antidiabetic and Antiobesity Effects in Male Mice.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","brand":"US Peptide Labs","offers":[{"title":"10mg","offer_id":44076492292183,"sku":"CW\/P-OXY10O","price":110.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/oral-oxytocin-10mg.png?v=1785621423"},{"product_id":"pt-141-oral-spray","title":"PT-141 Oral Spray","description":"\u003ch3\u003ePT-141 (Bremelanotide) — oral format\u003c\/h3\u003e\u003cp\u003eThis listing supplies the compound in an orally administered format rather than a lyophilized vial requiring reconstitution. Oral and sublingual routes are studied for peptides because they remove injection handling from the workflow, while raising well-documented questions about gastrointestinal stability and absorption that vary by compound and formulation. The research summarised below was generated across multiple routes; the reported-amounts table records the route for each figure. Nothing here claims equivalence between routes.\u003c\/p\u003e\u003cp\u003eBecause this oral format is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized PT-141 (Bremelanotide) vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003emelanocortin receptor agonist peptide\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003ePT-141, also known as bremelanotide, is a cyclic melanocortin analog studied for effects on central melanocortin pathways rather than vascular PDE5 signaling. Published studies examine subjective arousal, erectile-response measurements, pharmacokinetics, tolerability, and melanocortin receptor biology. Its research profile is distinct from metabolic melanocortins because MC4R-linked CNS signaling is a major focus.\u003c\/p\u003e\u003cp\u003eBremelanotide has an FDA-approved counterpart, Vyleesi, for a specific approved indication and labeled route. Research-grade PT-141 powder is not Vyleesi, is not an approved drug product, is Research Use Only, and is not for human consumption. Reported ranges below describe published clinical research or approved-product contexts as reference information only.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003ePT-141 activates melanocortin receptors, especially MC4R-relevant pathways in the central nervous system. Unlike PDE5 inhibitors, its studied effects are not primarily mediated by direct peripheral vasodilation. Research models focus on hypothalamic and limbic signaling, dopamine-related arousal circuits, and downstream autonomic effects. Because melanocortin receptors are distributed across tissues, pharmacodynamic work also tracks nausea, flushing, blood pressure, and route-dependent exposure.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003emelanocortin signaling\u003c\/li\u003e\n\u003cli\u003eMC4R neurobiology\u003c\/li\u003e\n\u003cli\u003esexual arousal pharmacodynamics\u003c\/li\u003e\n\u003cli\u003eCNS peptide signaling\u003c\/li\u003e\n\u003cli\u003epeptide pharmacokinetics\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003ePT-141 is studied by neuropharmacologists, sexual-medicine researchers, peptide chemists, and clinical pharmacology teams. Regulatory researchers distinguish approved bremelanotide products from research-grade material because formulation, labeling, and quality systems are not interchangeable.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e300 mcg – 10 mg\u003c\/td\u003e\n\u003ctd\u003esingle study administration\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eSubcutaneous PT-141 clinical pharmacology study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7.5 mg\u003c\/td\u003e\n\u003ctd\u003esingle crossover study administration\u003c\/td\u003e\n\u003ctd\u003eintranasal\u003c\/td\u003e\n\u003ctd\u003eIntranasal PT-141 plus sildenafil study in men with erectile dysfunction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1.75 mg\u003c\/td\u003e\n\u003ctd\u003eas labeled for the approved product\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eFDA-approved bremelanotide product label context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eResearch-grade lyophilized PT-141 is commonly stored cold, dry, and protected from light; reconstituted research solutions are generally refrigerated and used within the supplier's stated stability window.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003ePT-141 has been studied with PDE5-inhibitor contexts, but combining centrally active melanocortin signaling with other pharmacology changes safety and interpretation. Research designs should distinguish approved bremelanotide products from RUO PT-141 and should not convert clinical exposure data into personal protocols.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003ebremelanotide, PT-141, melanocortin receptor agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eBremelanotide is commonly described with an elimination half-life of roughly 2-3 hours in clinical pharmacology contexts.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003ewhat is the dosage for PT-141\u003c\/strong\u003e\u003cbr\u003ePublished PT-141 studies include subcutaneous and intranasal exposure ranges, and Vyleesi has its own approved label. Research-grade PT-141 is not Vyleesi and is not for human consumption.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow much bacteriostatic water for PT-141\u003c\/strong\u003e\u003cbr\u003eReconstitution examples often use 1-2 mL for 5-10 mg research vials. That only sets concentration for lab calculations.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePT-141 dosage per day\u003c\/strong\u003e\u003cbr\u003ePT-141 is not usually framed as a daily research compound in the core clinical literature. Frequency should be taken from the specific study being discussed.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePT-141 dosage chart\u003c\/strong\u003e\u003cbr\u003eA chart should keep subcutaneous study exposures, intranasal studies, and approved Vyleesi labeling in separate rows.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow long does PT-141 take\u003c\/strong\u003e\u003cbr\u003eClinical studies measure pharmacodynamic effects over hours after administration. Timing depends on route, formulation, and endpoint.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePT-141 half life\u003c\/strong\u003e\u003cbr\u003eBremelanotide is commonly cited around a 2-3 hour elimination half-life, though observed effects and study windows can extend beyond that.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ecan PT-141 be stacked\u003c\/strong\u003e\u003cbr\u003eIt has been studied in combination contexts, but that is not a personal-use endorsement. RUO PT-141 should not be used as an approved drug substitute.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16839319\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eAn effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/14999221\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eEvaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15833522\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eCo-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","brand":"US Peptide Labs","offers":[{"title":"10mg","offer_id":44076492324951,"sku":"CW\/P-PT10O","price":110.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/oral-pt-141-10mg.png?v=1785621428"}],"url":"https:\/\/uspeptidelabs.co\/collections\/oral-sprays.oembed","provider":"US Peptide Labs | High Quality American-made","version":"1.0","type":"link"}